[HTML][HTML] Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …
clinical management and isolation of patients with COVID-19. We evaluated an unselected …
Incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir
Importance Some patients treated with nirmatrelvir-ritonavir have experienced rebound of
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …
The coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with nirmatrelvir …
Background The uptake of nirmatrelvir plus ritonavir (NPR) in patients with coronavirus
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
disease 2019 (COVID-19) has been limited by concerns around the rebound phenomenon …
Rebound phenomenon after nirmatrelvir/ritonavir treatment of coronavirus disease 2019 (COVID-19) in high-risk persons
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …
SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy: an observational study
GE Edelstein, J Boucau, R Uddin, C Marino… - Annals of Internal …, 2023 - acpjournals.org
Background: Data are conflicting regarding an association between treatment of acute
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …
[HTML][HTML] Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on …
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort study
MS Durstenfeld, MJ Peluso, F Lin… - Journal of Medical …, 2024 - Wiley Online Library
Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …
[HTML][HTML] Nirmatrelvir–ritonavir and viral load rebound in COVID-19
AS Anderson, P Caubel… - New England Journal of …, 2022 - Mass Medical Soc
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19 | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following nirmatrelvir/ritonavir treatment
Background Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in patients at high risk
D Paraskevis, M Gkova, K Mellou… - The Journal of …, 2023 - academic.oup.com
Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …